Global B2B Pharmaceutical Sourcing · Dossier Licensing · Named-Patient Access
💬 WhatsApp · Sign in · Register
Febuxostat Extended Release tablets bulk supplier for pharma manufacturers

Febuxostat Extended Release Tablets 80mg Suppliers & Bulk Manufacturers

Available Forms: tablets

Available Strengths: 80mg

Reference Brands: Adenuric (EU/UK)

Category: Nephrology

Febuxostat is an oral xanthine-oxidase inhibitor indicated for long-term management of hyperuricaemia in patients with gout who require urate-lowering therapy. It is prescribed when allopurinol is unsuitable or not tolerated.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Product Description:

-

Febuxostat Extended Release Tablets — third party manufacturing & bulk supply

Febuxostat Extended Release Tablets 80mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.
Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.
Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

What to include when you enquire

  • Destination market — determines which manufacturers hold the right site-level approvals
  • First order quantity and estimated annual volume
  • Whether you need a registration dossier or the product is already registered
  • Packaging, labelling and language requirements
  • Incoterms and required shelf life

Manufacturers of Febuxostat Extended Release Tablets listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding. Narcotic drugs and controlled substances are supplied strictly against valid import and export permits issued by the competent authorities.

Request a quote for Febuxostat Extended Release Tablets →
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing

Frequently Asked Questions

Febuxostat is used to lower uric acid levels in the blood and prevent gout attacks in adults. Gout occurs when there is a buildup of uric acid crystals in the joints, leading to inflammation and pain. Febuxostat helps by inhibiting the enzyme xanthine oxidase, which is responsible for producing uric acid, thereby reducing its levels and preventing crystal formation.

Febuxostat is made from the active ingredient febuxostat, a non-purine selective xanthine oxidase inhibitor. Its chemical composition is 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid, along with inactive ingredients such as lactose monohydrate, microcrystalline cellulose, and magnesium stearate (depending on the formulation).

The most common trade names of Febuxostat are

Febuxostat (Uloric) is manufactured by

The generic name of the drug is

Brand names include

Febuxostat is manufactured in multiple regions, including

Related Products

Atrasentan Hydrochloride

Strength:
0.75 mg, 1.25 mg, 10 mg

Form: Tablets

Reference Brands: Xinlay (USA/EU), Vanrafia (USA/LATAM)

View Details
Tiopronin

Strength:
100 mg, 200 mg , 300 mg

Form: Tablets, Capsules

Reference Brands: Thiola (USA), Mercaptamine (EU)

View Details
Nedosiran

Strength:
80 mg, 160 mg

Form: Injection

Reference Brands: Ryplazim (USA)

View Details
Probenecid

Strength:
500 mg

Form: Tablets

Reference Brands: Benemid (USA)

View Details
Enquire Now

Quick Response Guaranteed | Verified Suppliers

Subscribe to Our Newsletter

Stay updated on pharma trends and sourcing opportunities.

Please enter the correct answer.
This website uses cookies to ensure you get the best experience. By using our site, you agree to our Privacy Policy.